What can be prescribed remotely, and by whom?
Remote prescribing of Schedule 2 stimulants is lawful where the prescriber is entitled to prescribe them and the clinical assessment behind the prescription genuinely meets the required standard, and both halves of that sentence carry weight. On entitlement: doctors can prescribe Schedule 2 controlled drugs, and nurse and pharmacist independent prescribers can prescribe controlled drugs across Schedules 2 to 5 within their competence, with narrow exceptions around treating addiction that do not touch ADHD practice. Under NICE guidance, ADHD diagnosis and treatment initiation sit with appropriately qualified specialist clinicians, which in the independent sector means consultant psychiatrists and specialist prescribers working within a service registered with the Care Quality Commission (CQC) for treatment.
On assessment: the remote modality does not dilute the clinical requirements, and this is exactly where the sector's 2026 scrutiny has landed. NICE expects a full assessment before stimulant treatment begins, including cardiovascular history and physical assessment, so a remote pathway must build the physical leg in deliberately rather than assuming video substitutes for it; some commissioners now mandate face-to-face physical checks for children before treatment, and prescribers working remotely should treat that as the direction of travel rather than a local anomaly. The General Medical Council's remote prescribing expectations point the same way: the prescriber must be able to carry out an adequate assessment through the chosen medium, and where they cannot, the medium changes, not the standard. It pairs with our analysis of the 2026 scrutiny, which covers why these rules are being watched; this piece covers what they are.
For the pharmacy, the entitlement question becomes a verification duty. Before dispensing any Schedule 2 drug the pharmacist must take reasonable steps to be satisfied the prescription is genuine and the prescriber is who and what the prescription claims, which for ADHD clinic prescriptions means checking the prescriber's registration, and for private prescriptions, the specific identifier covered next.
What must the prescription itself contain?
A private prescription for a Schedule 2 stimulant in England is only dispensable on form FP10PCD carrying the prescriber's six-digit private controlled drug prescriber identification number, alongside the full Schedule 2 prescription requirements, and a prescription missing the identifier should not be dispensed. This is the formality remote ADHD services most often get wrong at launch: the clinic's prescribers each need a private CD prescriber identification number issued through the relevant NHS agency before the first private prescription is written, prescriptions go on the designated form (WP10PCD in Wales, PPCD in Scotland), and a prescriber without a number gets directed to their NHS England team, not accommodated.
The quantity conventions matter operationally. Good practice limits Schedule 2 prescriptions to 30 days' supply, which most reputable ADHD services follow and which shapes the whole service model: a titration patient generates a fresh prescription every cycle, and there is no shortcut around that, because repeat prescriptions are not permitted on Schedule 2. Every month of treatment is a new prescription, a new dispensing episode and a new set of records, which is why prescription generation, transmission and tracking between clinic and pharmacy needs to run as a designed workflow rather than an email thread.
After dispensing, the paper has a destination: FP10PCD forms are submitted monthly to the NHS Business Services Authority with the FP34PCD submission document, by the fifth day of the following month, on the pharmacy's dedicated private CD account, with the pharmacy's own record of the supply retained for two years. The full mechanics, including the account setup a new pharmacy needs, are set out in our CBPM record-keeping guide, and they apply identically here because the rules are Schedule 2 rules, not medicinal cannabis rules.
How long does an ADHD prescription live, and what dies with it?
A Schedule 2 prescription is valid for 28 days from the appropriate date, no repeats are permitted, and any owing balance dies at the same 28-day mark, three rules that together define the operational tempo of an ADHD service. The appropriate date is the signing date or a later start date the prescriber has marked, whichever is later, and the 28-day life is unforgiving: a prescription that cannot be dispensed inside it needs reissuing by the prescriber, not stretching by the pharmacy.
The owings rule deserves particular attention in this category because of the supply environment. ADHD medication shortages have run through 2025 and 2026 across major lines, and the tempting response to a stock gap, dispense what you have and owe the rest, collides with the rule that the owed balance cannot be supplied more than 28 days after the appropriate date. An owing created against uncertain wholesale stock is frequently a promise the supply chain will break, and the better pattern is the one we set out for medicinal cannabis dispensing in the CBPM workflow guide: make the shortfall decision on day one and return it to the prescriber, who can switch preparation, adjust or reissue, rather than letting the clock decide. The wider shortage playbook, including what pharmacies can and cannot do when a line fails nationally, belongs to our forthcoming ADHD prescriptions handling guide.
Can a pharmacy make an emergency supply of ADHD medication?
No. Emergency supply at the request of a patient does not apply to Schedule 2 controlled drugs, so a pharmacy cannot supply methylphenidate, lisdexamfetamine or any other Schedule 2 stimulant to a patient who has run out, whatever the circumstances.
The claim circulating on patient-facing websites that pharmacists can supply up to five days of a Schedule 2 ADHD medicine at their discretion is simply wrong. The five-day limit being misremembered belongs to a different rule entirely, and the only controlled drug exception to the Schedule 2 and 3 emergency supply bar is phenobarbital for epilepsy, which has nothing to do with ADHD practice.
The rule has real consequences for service design, which is why it earns its own section. A patient between prescriptions has exactly one lawful route to medicine: a new prescription from a prescriber, and for a remote ADHD service that means the clinic's responsiveness is the patient's safety net. Build accordingly: a defined urgent-prescription route at the clinic with a same-working-day standard, pharmacy SOPs that direct out-of-medicine patients to that route immediately rather than improvising, and patient communications that set the expectation upstream, at dispensing, that reordering starts early because the pharmacy legally cannot bridge a gap.
"A service that discovers this rule through its first out-of-hours crisis has designed the crisis in."
What does the pharmacy owe the medicine itself?
Safe custody, register discipline and assured delivery: the stimulants are Schedule 2 stock, so they live in the controlled drugs cabinet, move through the CD register with running balances and prompt entries, and leave the building under arrangements built to reach the right person. None of this is ADHD-specific and all of it is non-negotiable.
Custody and register. Schedule 2 safe custody applies, the register records every receipt and supply with balances reconciled on a schedule, corrections are made by annotation rather than deletion, and the register is retained for two years from the last entry. At titration-service volumes, with every patient generating monthly dispensing episodes, the register workload compounds quickly and should be staffed and owned per session; a controlled drugs register module is scheduled for release on Dataforge PMR at the end of 2026, and until then the register runs as a disciplined parallel process alongside the PMR.
Collection and delivery. At a counter, Schedule 2 practice means the collector signs and the pharmacy asks for identification; a remote service translates that into the courier leg, which means tracked, signature-on-delivery service with safe-place and neighbour options disabled, delivery to the patient or a confirmed representative, plain packaging and the proof of delivery pulled back into the dispensing record. For a patient cohort that includes children and young people, the handover design should also reflect who may lawfully and sensibly receive the medicine, which is a parent or carer question the SOP answers in advance.
| Rule | What it means in a remote ADHD service |
|---|---|
| Schedule 2 classification | Safe custody, CD register, full prescription formalities |
| 28-day validity, no repeats | Fresh prescription every cycle; titration is a prescription-generation workflow |
| 30-day quantity good practice | Monthly dispensing tempo; reorder communications built upstream |
| FP10PCD plus prescriber identifier | Clinic prescribers need private CD numbers before launch; no identifier, no dispensing |
| Monthly NHSBSA submission | FP34PCD by the fifth, on the private CD account |
| Owings die at 28 days | Day-one shortfall decisions, not hopeful part-fills |
| No emergency supply | Clinic urgent-prescription route is the only safety net |
| Delivery assurance | Signature-required, no safe-place, POD filed with the dispensing record |
Where do clinic and pharmacy responsibilities meet?
They meet at verification and at the record, and a remote ADHD service is only as defensible as that interface. The pharmacy verifies the prescriber (professional registration, private CD identifier, and for a new clinic relationship, provenance established independently of the prescription itself) and records the check; the clinic ensures its prescriptions are formally perfect and its prescribers properly credentialed before volume starts; and both sides hold records that let either reconstruct any supply months later, from assessment through prescription to signed-for delivery.
The interface is also where governance reflects in both directions, a point the 2026 scrutiny has made unavoidable. A pharmacy dispensing for an ADHD clinic is lending its registration to that clinic's clinical model, so the pharmacy's onboarding diligence on a clinic partner should look at the assessment pathway, the physical-check arrangements and the titration records, not just the projected volumes. Equally, a clinic choosing a dispensing partner should demand evidence of the rules in this guide running as workflow. The structural version of that relationship, including when clinic and pharmacy belong under one corporate roof, is the subject of our forthcoming piece on the clinic-plus-pharmacy model, and the systems that make the shared record real are covered in the forthcoming IT gap in ADHD and titration services.
Key takeaways
- ADHD stimulants are Schedule 2 controlled drugs, and every rule in this guide flows from that classification, not from anything ADHD-specific.
- Prescriptions live 28 days from the appropriate date, carry no repeats, and owed balances die at the same mark, setting a monthly tempo the whole service runs on.
- Private prescriptions require form FP10PCD and the prescriber's six-digit private CD identification number, without which the pharmacy does not dispense, and dispensed forms go to the NHSBSA monthly.
- There is no emergency supply of Schedule 2 medicines at patient request, the five-day discretion claim circulating online is wrong, and the clinic's urgent-prescription route is the only lawful bridge.
- Remote prescribing is lawful but the NICE assessment standard, including physical and cardiovascular assessment, travels with it, and commissioners are already mandating face-to-face checks for children.
- The pharmacy owes the stock safe custody, a reconciled register and signature-assured delivery with no safe-place options.
- Clinic and pharmacy meet at verification and records, and each is lending the other its regulatory standing, so diligence runs both ways.
FAQs
Rules that run as workflow.
The workflow these rules demand is what Dataforge PMR carries on the pharmacy side: assessments with custom fields tracking titration observations over time, prescriber records and notes in one audit-trailed platform, reminders driving the monthly cycle and review recalls, and dispensing with drug label printing, with the controlled drugs register module scheduled for release at the end of 2026. Our publisher also writes the SOP suites and clinic-pharmacy interface documentation behind services like these. If you are building or auditing an ADHD service, book a 30-minute call.
Book a call